Parabilis Medicines (PBLS) Stock Price & Analysis
AI Analysis
SnapshotParabilis Medicines is a growth-led story right now — Growth 93/100 is the pillar doing the heavy lifting (overall 63/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~33% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Parabilis Medicines, Inc. (PBLS) last printed $30.02. Equity value is $3.66B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2024 | 2025 |
|---|---|
| $0.00 | $0.00 |
About
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.